| P2093 | author name string | Eva G Rakasz | |
| | Guangping Gao | |
| | Ronald C Desrosiers | |
| | Sebastian P Fuchs | |
| | José M Martinez-Navio | |
| | Sònia Pedreño-López | |
| P2860 | cites work | Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. | Q39501844 |
| | Woodchuck hepatitis virus post-transcriptional regulatory element deleted from X protein and promoter sequences enhances retroviral vector titer and expression | Q40365103 |
| | Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities | Q41753346 |
| | Several rAAV vectors efficiently cross the blood-brain barrier and transduce neurons and astrocytes in the neonatal mouse central nervous system | Q42012887 |
| | HIV vaccine design and the neutralizing antibody problem | Q46474020 |
| | Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning | Q46683819 |
| | Characterization of the three immunoglobulin G subclasses of macaques | Q47959086 |
| | IMGT gene identification and Colliers de Perles of human immunoglobulins with known 3D structures | Q48316781 |
| | IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. | Q51050948 |
| | IMGT/V-QUEST: IMGT standardized analysis of the immunoglobulin (IG) and T cell receptor (TR) nucleotide sequences | Q84245408 |
| | Antibody responses to envelope glycoproteins in HIV-1 infection | Q26991572 |
| | Antibodies in HIV-1 vaccine development and therapy | Q27011574 |
| | Adeno-associated virus at 50: a golden anniversary of discovery, research, and gene therapy success--a personal perspective | Q27012320 |
| | AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity | Q27318266 |
| | Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions | Q27478005 |
| | Adeno-associated virus: from defective virus to effective vector | Q27498163 |
| | Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding | Q27670829 |
| | Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies | Q27674878 |
| | Broad and potent neutralization of HIV-1 by a gp41-specific human antibody | Q27675131 |
| | Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike | Q27683540 |
| | pERp1 is significantly up-regulated during plasma cell differentiation and contributes to the oxidative folding of immunoglobulin | Q28510139 |
| | Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies | Q28602877 |
| | Antibody neutralization and escape by HIV-1 | Q29547345 |
| | Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target | Q29547347 |
| | Broad neutralization coverage of HIV by multiple highly potent antibodies | Q29615361 |
| | Rapid evolution of the neutralizing antibody response to HIV type 1 infection | Q29618603 |
| | Predominant autoantibody production by early human B cell precursors | Q29619656 |
| | A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice. | Q30559496 |
| | Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. | Q33643620 |
| | Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques | Q33826773 |
| | AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges | Q34464133 |
| | Self-complementary AAV vectors; advances and applications | Q34804660 |
| | Gene therapy using adeno-associated virus vectors | Q34852719 |
| | B-cell repertoire responses to varicella-zoster vaccination in human identical twins | Q34985620 |
| | Antibody-based protection against HIV infection by vectored immunoprophylaxis | Q35658856 |
| | Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection | Q35914292 |
| | Recombinant adeno-associated virus transduction and integration | Q36953325 |
| | Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys | Q37295534 |
| | How antibodies fold | Q37659557 |
| | Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | Q37866086 |
| | The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer | Q38539938 |
| P433 | issue | 1 | |
| P304 | page(s) | 76-86 | |
| P577 | publication date | 2015-10-07 | |
| P1433 | published in | Molecular Therapy | Q15762400 |
| P1476 | title | Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys | |
| P478 | volume | 24 | |